Please go to the PowerPak homepage
and select a course.
Addressing the Barriers to Effective Overactive Bladder Management Through Medication Therapy Management
This activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Astellas Pharma US, Inc.
Demetra E. Antimisiaris, PharmD, CGP, FASCP
Associate Professor, Pharmacology and Toxicology
University of Louisville School of Medicine
Director, University of Louisville Geriatric Pharmacotherapy Clinical Service
Demetra Antimisiaris, PharmD, CGP, FASCP, has indicated that she has no relevant affiliations or financial relationships with a commercial interest to disclose.
The following reviewer, Mary M. Bridgeman, PharmD, BCPS, states that she has no financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.
Susanne Batesko, RN, BSN, Michele Salernitano, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 1.0 hours (0.10 ceu)
Published: March 1, 2016
Expires: March 1, 2017
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity
Estimated time to complete activity: 60 minutes
This accredited activity has been designed for pharmacists.
HOW TO EARN CREDIT
During the period March 1, 2016 through March 1, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
The goal of this activity is to provide an update for pharmacists about the management approaches for overactive bladder (OAB), including obstacles and barriers to diagnosis and effective treatment, optimizing the therapeutic selection, and adherence issues.
Upon completion of this activity, participants should be better able to:
- Discuss barriers that prevent patients from receiving diagnosis and effective treatment of overactive bladder (OAB);
- Describe the economic and quality of life impact of OAB and the influence of this condition on older adult patients and those with medical comorbidities;
- Review current guideline statement recommendations for OAB and identify updates or changes related to newer therapeutic approaches;
- Determine methods pharmacists can use to identify and discuss adherence issues with OAB treatment regimens; and
- Explain the applicability of medication therapy management (MTM) services in OAB and how these can be implemented in pharmacy practice.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC and Astellas Pharma US, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients' conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer's product information, as well as a comparison with the recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.